LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 5 of 483
Next
>>
>
101 to 125 of 12072 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CGP60474	0.04	uM	LJP6	2	G06	72	hr	1334	774	3970	0.1949	-0.2127
BT-20	CGP60474	0.04	uM	LJP6	3	G06	72	hr	1334	762	3970	0.1919	-0.2172
BT-20	CHIR-99021	0.04	uM	LJP6	1	P18	72	hr	1334	3019	3970	0.7603	0.6389
BT-20	CHIR-99021	0.04	uM	LJP6	2	P18	72	hr	1334	3727	3970	0.9386	0.9075
BT-20	CHIR-99021	0.04	uM	LJP6	3	P18	72	hr	1334	3800	3970	0.9570	0.9352
BT-20	CP724714	0.04	uM	LJP5	1	A12	72	hr	1334	3557	3970	0.8958	0.8430
BT-20	CP724714	0.04	uM	LJP5	2	A12	72	hr	1334	3806	3970	0.9585	0.9374
BT-20	CP724714	0.04	uM	LJP5	3	A12	72	hr	1334	4040	3970	1.0174	1.0262
BT-20	CP466722	0.04	uM	LJP5	1	I12	72	hr	1334	4070	3970	1.0250	1.0376
BT-20	CP466722	0.04	uM	LJP5	2	I12	72	hr	1334	4312	3970	1.0859	1.1294
BT-20	CP466722	0.04	uM	LJP5	3	I12	72	hr	1334	4339	3970	1.0927	1.1396
BT-20	Crizotinib	0.04	uM	LJP5	1	A24	72	hr	1334	3289	3970	0.8283	0.7413
BT-20	Crizotinib	0.04	uM	LJP5	2	A24	72	hr	1334	3166	3970	0.7973	0.6947
BT-20	Crizotinib	0.04	uM	LJP5	3	A24	72	hr	1334	3521	3970	0.8867	0.8293
BT-20	Momelotinib	0.04	uM	LJP5	1	P12	72	hr	1334	4024	3970	1.0134	1.0201
BT-20	Momelotinib	0.04	uM	LJP5	2	P12	72	hr	1334	3908	3970	0.9842	0.9761
BT-20	Momelotinib	0.04	uM	LJP5	3	P12	72	hr	1334	4042	3970	1.0179	1.0270
BT-20	Dasatinib	0.04	uM	LJP5	1	D06	72	hr	1334	3341	3970	0.8414	0.7611
BT-20	Dasatinib	0.04	uM	LJP5	2	D06	72	hr	1334	3400	3970	0.8562	0.7834
BT-20	Dasatinib	0.04	uM	LJP5	3	D06	72	hr	1334	3624	3970	0.9126	0.8684
BT-20	Dasatinib	0.04	uM	LJP6	1	I06	72	hr	1334	3058	3970	0.7701	0.6537
BT-20	Dasatinib	0.04	uM	LJP6	2	I06	72	hr	1334	2901	3970	0.7306	0.5942
BT-20	Dasatinib	0.04	uM	LJP6	3	I06	72	hr	1334	2781	3970	0.7003	0.5486
BT-20	Dovitinib	0.04	uM	LJP5	1	E24	72	hr	1334	3107	3970	0.7824	0.6723
BT-20	Dovitinib	0.04	uM	LJP5	2	E24	72	hr	1334	3721	3970	0.9371	0.9052

|<
<<
Previous
Page 5 of 483
Next
>>
>
101 to 125 of 12072 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)